Taysha Gene Therapies, Inc. (TSHA)
5.36
-0.07
(-1.29%)
USD |
NASDAQ |
Jun 09, 16:00
5.30
-0.06
(-1.12%)
After-Hours: 20:00
Taysha Gene Therapies Research and Development Expense (Quarterly) : 33.51M for March 31, 2026
Research and Development Expense (Quarterly) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Data
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Research and Development Expense (Quarterly) Benchmarks
| BioCryst Pharmaceuticals, Inc. | 59.26M |
| Agenus, Inc. | 11.82M |
| Amgen, Inc. | 1.719B |
| Imunon, Inc. | 2.337M |
| Curis, Inc. | 6.449M |